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During the last ten years, several patients have presented to the Renal Unit of Groote 
Schuur Hospital with acute renal failure following the use of traditional (N'anga or Gqirha) 
medication. The history together with abnormal liver-function tests and renal failure was 
thought to be suggestive of a toxic aetiology. The specific toxin however remained unknown, 
until during the admission of one patient, a relative brought in the medication, analysis of 
which revealed a high concentration of potassium dichromate. Subsequently elevated levels 
of chromium were demonstrated by atomic absorption spectrometry in the blood and urine 
of this patient. Following this case there have been six further cases of acute renal failure 
resulting from use of dichromate containing traditional remedies. These remedies were 
obtained from a variety of sources including street-hawkers, herbal chemists, and traditional 
healers. Clinical and laboratory data relating to these seven patients will be presented. 
The use of dichromate in traditional medicines is not limited to present-day Africa. In 
1925 a young Indian woman died following the ingestion of a dichromate containing medicine 
prescribed by a travelling "Hakim" (1), and in 1940 two further deaths were reported in Uttar 
Pradesh Province, India after use of dichromate in traditional medicine (2). 
Emetics and purgatives are commonly used in African tribal medicine (3). Traditionally 
enemas were dispensed via a truncated cow-horn, and consisted of vegetable material such 
as roots, herbs, tree-bark, and leaves. A recent series published from Baragwanath Hospital 
reported serious gastro-intestinal complications following use of "toxic enemas" and noted that 
they contained irritant substances such as Dettol chloroxylenol), vinegar, battery acid, 
potassium permanganate, copper sulphate and potassium dichromate (4). This latter substance 
is a mucosal irritant and it is this property which is being exploited by its incorporation into 
N'anga / Gqirha purgatives. Dichromate appears as the principal active ingredient of many 
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of the enemas that have been available for analysis. In contrast to metallic chromium which 
is biologically inert, dichromates containing hexavalent chromium are highly reactive with 
powerful oxidising properties. They are readily available, being used in a variety of industrial 
processes, including electro-plating, leather tanning and industrial and laboratory cleansing 
solutions. Hexavalent chromium is locally irritant to mucosa! and epithelial surfaces. Topical 
exposure may lead to dermatitis and indolent mucocutaneous ulceration (5). Pulmonary 
exposure to chromic acid fumes may result in chronic bronchitis, interstitial pneumonitis, 
progressive pulmonary fibrosis and an increased incidence of bronchogenic carcinoma (6). 
Acute overdoses of chromium compounds, usually via the oral route and accidental, have only 
been infrequently described in the medical literature (7 - 22). The lethal oral dose of 
potassium dichromate can be as little as 0,5 - 1,0 gms (23), leading to acute tubular necrosis, 
gastrointestinal tract haemorrhage, hepatitis, haemolytic anaemia and encephalopathy. Little 
is known or has been published concerning the pathogenesis of dichromate toxicity. It will be 
shown that the toxicity of hexavalent chromium is related to its ability to readily penetrate 
cell membranes and its subsequent reactions with intra-cellular components. A hypothesis will 
be put forward that these intra-cellular reactions and in particular the presence of intra-
cellular reducing agents are the determinants of organ injury by hexavalent chromium. 
The literature relating to the use of radioactive chromium (Cr 51) as a label ofred cells 
and plasma proteins will be reviewed. Data from this literature will be used to illustrate the 
effect of the valency state of chromium on its pharmacokinetics. Data relating to the body 
distribution of chromium will be presented in the form of post mortem tissue analysis from 
four cases of fatal dichromate poisoning. 
Treatment regimens for dichromate poisoning remain largely unproven having been 
derived from animal studies together with only infrequent case reports. In particular there 
is controversy in the medical literature concerning the effectiveness of dialysis in the 
elimination of body chromium. Dialysis and renal chromium clearance data will be presented 
and correlated with chromium concentrations in the red cell, plasma protein and plasma water 
compartments. The variable dialysability of each of these compartments will be put forward 
as a hypothesis to explain the apparently conflicting dialysis data in the literature. 
CHEMISTRY 
Chromium belongs to the first series of the transitional elements with an atomic number of 
24 and a mass of 52,01. Chromium can occur in every oxidation state (valency) from -2 to + 6, 
but only the ground states of 0, + 2, + 3 and + 6 are common. The divalent compounds are only 
stable if protected from oxidation which takes place easily in air. 
Cr3+ + e- = Cr2+ , E = 410 mv 
Because of this very strong reducing power, divalent chromium compounds are unlikely to 
occur in biological systems. 
The hexavalent forms of chromium are usually linked with oxygen, the two important 
ions being chromate (Cr 0 4
2
·) and dichromate (Cr2 Ol ). Both chromate and dichromate are 
strong oxidising agents and can be reduced in acidic solutions to the trivalent form. 
Cr2 Ol + 14 H+ + 6e· = 2Cr3+ + 7 H2 0 , E = 1,33 V 
The hydroxyl groups of organic compounds are readily oxidised to ketones or aldehydes 
by this reaction. This can be observed when organic material contaminates dichromate 
containing cleaning solutions, the orange colour of dichromate changing to the characteristic 
green colour of trivalent chromium. The toxicity of hexavalent chromium is related to its 
solubility and this potential for oxidising organic material. As a result of this reaction the 
toxicity of dichromate containing medications can theoretically be affected in several ways. 
The presence of organic material or reducing agents in the medication could reduce the 
effective concentration of hexavalent chromium available for absorption. The time between 
mixing the ingredients and ingestion would also vary the extent to which this reaction could 
proceed and lastly the pH of the medication and gut contents would vary the rate of this 
reaction. 














characteristically has a strong tendency to form co-ordination compounds, complexes, and 
chelates. It is probably in the trivalent form that chromium is required as a trace element for 
glucose tolerance and as a structural stabilising factor for D.N.A and R.N.A. Trivalent 
chromium has a co-ordination number of 6 with the direction of the ligands pointing to the 
corners of an octahedron (Fig 1). 
Common ligands include water, ammonia, urea (not charged) or anions such as halides, 
sulphate and anions of organic acids. Free chromic ion does not exist in aqueous solution; it 
is always co-ordinated with either water or other ligands in solution. These other ligands tend 
to replace the water so that mixed complexes (chelates) result (Fig 2). These complexes are 
stable at acid pH ( <4) however as the concentration of hydroxyl groups increases, hydrolysis 
of the co-ordinated water results in co-ordination of hydroxyl groups (Fig 3). 
Hydrolysis can also result in cross linkage between chromium molecules proceeding 
onto the formation of polynuclear complexes a process called olation (Fig 4). Olation is an 
important process in the chrome tanning of leather whereby trivalent chromium cross-links 
protein molecules. 
If olation is allowed to proceed unhindered macro-molecular colloidal complexes 
precipitate out of solution and these complexes will be biologically inert. Simple trivalent 
chromium compounds are insoluble at neutral pH, however because of the strong propensity 
for olation, ligands capable of competing with hydroxyl groups are able to keep trivalent 
chromium in solution. Powerful ligands are able to displace hydroxyl groups and solubilise 
previously insoluble complexes. An example of this is seen when oxalate is used to detan 
leather. This property of powerful ligands may be important in dialysis where organic acid 
radicals are used in high concentration in dialysate as buffers. The lactate concentration of 















HOH OH- OH- HOH 






Several aspects of the above chromium chemistry are of particular biological 
significance. The differences in oxidative potential between divalent and trivalent and between 
trivalent and hexavalent chromium are so great that reversible transition between the 
oxidative states is extremely unlikely to occur in biological systems. At physiological pH and 
in the presence of reducible radicals, hexavalent chromium will always tend to be reduced to 
the more stable trivalent form. The toxicity of hexavalent chromium results from both its 
solubility and the propensity to react with organic material especially by oxidising alcohol 
groups. 
Simple trivalent chromium compounds are insoluble at physiological pH and are 
relatively biologically inert, however by means of olation and ligand exchange they can develop 
into both macro-molecular colloidal or soluble complexes. Soluble complexes with lactate or 
acetate are able to cross dialysis membranes and may be the form in which trivalent 
chromium is dialysable. 
METABOLISM 
ABSORPTION : Trivalent chromium is poorly absorbed from the gastro-intestinal tract; 
experimentally between 0,5% and 3% of an oral dose of chromic chloride is retained. 
Chromium is present in the diet in both inorganic and organically complexed forms. 
Experimentally chromium absorption is measured from total body counting after 
administration of Cr 51 or by urinary chromium output. Both these methods would 
underestimate absorption if significant excretion occurred via the gut as suggested by Hopkins 
(24). Visek et al (25) reported absorption of less than 0,5% of an oral dose of chromic chloride 
in the rat. Donaldson and Barreras (26) found that only 0,1-1,2% of an oral dose appeared in 
the urine of patients. A somewhat higher retention of 2-3% was recorded in rats receiving 
chromic chloride by stomach tube (27) and the intestinal absorption was independent of the 
dose given. The normal urinary chromium excretion in man of 2-6 micrograms/I with a diet 
containing an average of 80 micrograms (26) of the element would require an absorption of 
between 2,5 and 7,5%. Offenbacher and Pi-Sunyer (28) point out that chromium like other 
trace elements is subject to chemical interactions in the small bowel with both dietary 
(exogenous) and intestinal (endogenous) factors which may affect its absorption in various 
ways. Substances such as amino-acids chelate chromium in the small bowel and prevent it 
from precipitating at the alkaline pH of the intestine. Phytate decreases and oxalate increases 
chromium absorption in the rat. Diets high in simple sugars increase urinary excretion of 
chromium in humans. 
Hexavalent chromium is a much less stable form of chromium which is not a normal 
biological constituent of the diet. Neither the site nor the mechanism of absorption is known. 
In view of the homology with sulphate and phosphate anionic radicals, chromates may be 
absorbed similarly. Donalson and Barreras reported (26) 2,1 % absorption of chromate on the 
basis of urinary excretion. Hanskey and Connell (29) utilised radio-active chromate as a non-
absorbable tracer to estimate gut transit time, with less intestinal absorption than trivalent 
chromic chloride. By the nature of the marked toxicity of hexavalent chromium only small 
quantities can be used in absorption studies and under these circumstances the interaction 
with exogenous and endogenous factors is crucial, as chromate can rapidly be reduced to the 
insoluble trivalent form. Beyermann and Eschnauer (30) reported that when chromate was 
added to wine in concentrations of 0,1-50ppm (mg/1) it was completely reduced within 30 
seconds. This effect can be overcome at higher doses of chromate, 100 mg/1 retaining 2% 
chromate activity. Hanskey and Connell (29) administered the labelled chromate in tomato 
or orange juice, both of which could be expected to contain reducing agents such as ascorbic 
acid. Hexavalent chromium is soluble and readily penetrates cells and its absorption is 
determined by the extent of reduction which takes place by interaction with exogenous and 
endogenous reactants. This in turn is dependent on the dosage of chromate and the low pH 
of the stomach which predisposes to its reduction to the trivalent form. 
TRANSPORT AND DISTRIBUTION 
The application of radio-active labelling with chromium 51 (Cr 51) isotope to blood 
components has increased our knowledge of red cell and plasma protein survival and turnover. 
These techniques have also increased our knowledge of the body handling of chromium. With 
the development of high intensity isotopes these studies have used relatively small quantities 
of chromium compounds. It should be remembered that in the situation of high dosage, as 
in chromate toxicity, the normal binding mechanisms may be overwhelmed and organ 
distribution may not parallel these low dose experiments. Gray and Sterling in 1950 (31) 
described the labelling of red cells and plasma proteins with Cr 51. They noted that cationic 
trivalent chromium did not penetrate the intact red cell although it readily bound to free 
haemoglobin, this was felt to be a reflection of the relative impermeability of the red blood 
cell to cations. When mixed with serum in-vitro, chromic chloride bound to both the albumin 
and globulin fractions, the presence of chelating agents such as citrate inhibits this binding. 
The bond with albumin was very strong and able to resist prolonged dialysis without losing 
the chromium tag. Walker-Smith et al. (32) described in-vivo plasma-protein labelling with 
intravenous trivalent Cr 51, the binding was rapid and able also to resist dialysis. An early, 
large and unpredictable urinary loss of radioactivity (18-61 %) was noted. This urinary 
chromium is dialysable, not protein bound and the renal clearance is related to the blood 
concentration of dialysable (non-protein bound) chromium not the protein bound fraction (33). 
Van Tongeren and Majoor (34) showed that the Cr 51 label on albumin shifted to untagged 
transferrin and that this translocation could be prevented by the addition of small quantities 
of ferric chloride. They concluded that the affinity of transferrin for iron was greater than for 
chromium. The in-vivo half-life of Cr 51 tagged albumin (6-9 days) was shown to be 
considerably less than that of iodine 131 (l.131) tagged albumin (21-24 days) and it was 
11 
postulated that because of the translocation of chromium to transferrin, the measured 
albumin half-life approximated to that of transferrin (8.7 days). 
Hexavalent chromium (Cr VI) behaves very differently from trivalent chromium (Cr 
III), being taken up by red cells and subsequently reduced to the trivalent form within the 
cell. In-vitro this uptake is rapid with 98,3% of the Cr 51 uptake occurring within 25-45 
minutes (35), the rate of uptake is diminished at a pH above 7 ,0 (36). The percentage of Cr 
51 taken up by the red cell is not appreciably influenced by the amount of chromate ion 
present, within the range of 0,25-10,0 micro-grams per millilitre of blood. Within the red cell 
the chromium is in the trivalent form, bound to the Beta chain of the haemoglobin molecule 
(37). There is a small elution of approximately 1 % per day of chromium from the cell but the 
remainder of the activity remains for the life-span of the red cell. Following cell death a 
proportion of the chromium appears in the urine in the trivalent form, the rest largely 
accumulates in the liver if the haemolysis is intravascular, or in the spleen if haemolysis is 
extravascular (36). During in-vitro labelling of red cells a small proportion of the hexavalent 
chromium is reduced to the trivalent form at the cell surface. If the cells are not washed prior 
to infusion, this chromium is rapidly excreted in the urine. With the use of high activity 
isotopes red cell survival is not shortened by the labelling technique, but at higher 
intracellular chromium concentrations, red cell metabolism is impaired. At an intracellular 
chromium concentration of 10 mg/1 there is significant depression of glycolysis, at 5-25 mg/1 
glutathione reductase activity is inhibited, and above 22mg/l methaemoglobin concentrations 
rise (36). Visek et al. (25) administered small quantities of Cr 51 (50 micro-curies) to rats in 
the form of intravenous sodium chromate and chromic chloride. With sodium chromate the 
major uptake was by the liver with 25% of the activity deposited in that organ in 30 minutes 
after administration, and a urinary excretion of 35% in the first 4 days (Table I). Animals 
sacrificed on day 4 had the highest tissue chromium concentration in the kidneys, with lower 
but significant amounts in the blood, liver, spleen and bone marrow. By contrast, after 
chromic chloride injection there were high concentrations in liver, spleen and bone marrow 
but low concentration in the kidneys. The only tissue which accumulated activity with time 
was the spleen, probably because of accumulation of red cell chromium. Danielsson et al (38) 
injected pregnant mice with much larger doses of Cr 51 (lOmg/kg), in the form of intravenous 
sodium dichromate and chromic chloride (Table II). Again the same pattern is seen, with 
hepatic accumulation with both Cr III and Cr VI but high renal accumulation only with Cr VI. 
A modest placental transfer to the fetus was noted with Cr VI, but only minimal transfer with 
Cr III. Tsapakos et al. (39) injected rats with intraperitoneal sodium dichromate at high 
dosage (20 and 40 mg/kg) and again significant amounts of Cr were present in renal and 
hepatic tissue by 1 hour. The concentration in the nuclei reached a maximum at 4 hours with 
the 20 mg/kg dose and at 12-24 hours with the 40 mg/kg dose. The significance of this 
intranuclear concentration of Cr will be considered later in the discussion on the toxicology 
of Cr VI. 
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TABLE 1. Taken from Visek et al. 
Summary of behavior of Cr 51 in rats following intravenous administration in 
different chemical forms. 
N~Cr04 CrCl3 CrCl3 + Citrate 
% in urine 35 (1,9) 15 (1,3) 75,1 (9,3) 
Liver ,52 (,06) 5,5 (,69) ,31 (,12) 
Spleen ,91 (,16) 3,2 (,35) ,76 (,28) 
Kidney 2,1 (1,1) ,44 (,02) ,13 (,07) 
Bone Marrow ,56 (,14) 1,5 (,23) ,13 (,08) 
Blood ,52 (,07) <,02 <,02 
Tissue values are on day 4 post injection of 50 micro-curies Cr 51 and represent% of dose per 
gm of fresh tissue. Standard error in brackets (n=4). 
Table II. Taken from Danielsson et al. 
Comparison of concentrations of Cr 51 in rat fetuses and maternal organs 1 hour 
after intravenous injection of sodium dichromate or chromic chloride at dose of 10 
mg Cr/kg. 
Cr VI Cr III 
Fetus 0,3 (,01) 0,03 (,002) 
Liver 29,4 (2,2) 30,8 (6,5) 
Kidney 38,1 (1,9) 5,3 (,7) 
Serum 2,6 (,2) 9,3 (,9) 
Concentrations are mg Cr /kg. Standard error in brackets (n = 4). 
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EXCRETION 
The main route for chromium excretion is renal, however there may also be a smaller 
intestinal loss. Visek et al. (25) using rats in metabolic cages reported a 20% faecal excretion 
after intravenous Cr III and 17% after Cr VI. Metabolic cages may not exclude urine 
contaminating faeces. Hopkins (24) reported a faecal excretion of 0,5-1, 7% and avoided urine 
contamination of faeces by killing rats within a few hours of the administration of intravenous 
chromium. Enteric loss of plasma proteins has been studied in humans, using Cr 51 tagged 
proteins. Inflammatory bowel disease is associated with considerable intestinal protein loss. 
Walker-Smith et al.(32) using intravenous Cr III reported up to 17,1% faecal chromium in a 
patient with small bowel melanomatosis, but in the 9 control patients the faecal loss was less 
than 1% of the injected dose. Van Tongeren and Reichert (40) using a similar technique 
expressed intestinal protein loss as a clearance of Cr 51-labelled protein per unit of time. 
Patients without gastroenteropathy had plasma clearances of up to 13ml per 24 hours, whilst 
patients with protein-losing enteropathy had clearances of up to 600ml per 24 hours. These 
data demonstrate that in the normal human, the gut excretion of Cr III is minimal. There is 
little information concerning Cr VI intestinal excretion, but as gastroenteritis is a feature of 
Cr VI toxicity even if it is not taken orally (21), significant intestinal loss may be expected. 
Renal excretion has been shown in both animals and humans to be the main route of 
chromium elimination. Visek et al. (25) reported that 35% of intravenous Cr VI and 15% of 
Cr III appeared in the urine of rats within 4 days. The urinary clearance of Cr III was greatly 
increased to 56% if the Cr III was administered with acetate and to 75,1 % with citrate as a 
buffer. Walker-Smith et al. (32) noted that most of the urine loss of Cr III, occurring during 
in-vivo labelling of plasma proteins was in the first few hours. Collins et al. (33) showed in the 
dog, that after intravenous Cr III the dialysable portion of Cr decreased exponentially but the 
renal clearance of dialysable Cr remained constant. This is an important concept as it follows 
that renal and dialysis clearances are not directly related to blood or plasma chromium 
concentration, but to the dialysable portion, which is that portion co-ordinated to small 
molecular weight ligands. There is very little protein-bound Cr excreted in the urine, most 
being in the dialysable form. Tubular reabsorption was approximately 63% of the amount 
filtered (33). Stable chelates such as Cr 51-labelled E.D.T.A are not reabsorbed and can be 
used to accurately measure glomerular filtration rate (GFR.). Tubular reabsorption may 
account for the high concentrations of Cr found in renal tissue after exposure to Cr III 
however Cr VI has been shown to bind directly with proximal tubular cells without the need 
to be first filtered (41). As Cr VI is rapidly cleared from the serum by erythrocytes, 
hepatocytes, and proximal tubular cells it would be unlikely to appear in the urine for more 
than a few minutes after absorption, thereafter being in the more stable Cr III form. For 
example the early urine loss of Cr 51 seen after infusion of chromate tagged red cells is in the 
Cr III form (36). 
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TOXICOLOGY 
Trivalent chromium is relatively non-toxic, with toxicity restricted to parenteral 
administration only. The lethal to therapeutic ratio is greater than 10,000 : 1, and the LD.50 
of intravenous Cr ill hexaurea chloride in rats is between 100 and 180 mg/kg (42). 
Hexavalent chromium (Cr VI) is locally irritant to skin and mucosa! surfaces and poses 
a significant occupational health hazard to chrome workers. The respiratory conditions 
reported include ulcers and perforation of the nasal septum, sinusitis, laryngitis, chemical 
pneumonitis, and bronchogenic carcinoma (6). Dermatological complications include contact 
dermatitis and indolent skin ulcers (chrome holes). An increased susceptibility to 
gastrointestinal inflammatory and ulcerative diseases has also been reported (43). Acute Cr 
VI toxicity is rare, reports in the medical literature are usually isolated in nature and 
following accidental ingestion or suicide attempts (7 - 22). Gastrointestinal complications 
following the use of toxic enemas have been reported from Baragwanath Hospital (44) and in 
two of their 11 patients it was suspected that the enemas contained dichromate. Seven cases 
of acute Cr VI poisoning are reported here following the use of toxic "traditional" remedies. 
Acute Cr VI toxicity is usually manifested by dysfunction of those organs in which Cr VI is 
preferentially concentrated. Clinically this includes hepatitis, severe gastroenteritis, acute 
renal failure and rarely haemolytic anaemia (16). The high uptake in these tissues can be 
explained by an uptake-reduction mechanism. At physiological pH Cr VI readily enters cells 
(35,45) and is subsequently reduced by cellular components such as the microsomal electron-
transport cytochrome P-450 system (46) and glutathione (47). During the reduction process 
highly reactive intermediates may be formed, such as Cr IV and Cr V which subsequently bind 
to cellular structures. Cr V complexes have been demonstrated by electron spin resonance 
studies in cell cultures treated with Cr VI (48). The final reduction product of intra-cellular 
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Cr VI is the more stable Cr III, this intra-cellular conversion explains the uni-directional 
uptake of Cr VI by metabolically active cells. Tsapakos et al. demonstrated DNA inter-strand 
and DNA-protein cross-links in liver and kidney nuclei of rats exposed to intraperitoneal Cr 
VI (39). Similar nuclear lesions were seen in cultured chick hepatocytes exposed to Cr VI and 
these changes were parallelled by an inhibition of drug-mediated enzyme induction (45), an 
activity which requires both transcription and translation. Cupo and Wetterhahn (46) showed 
that DNA strand-breaks dramatically increased in Cr VI exposed hepatocytes when 
intracellular glutathione and P-450 levels were high and virtually disappeared when levels 
were low. These results suggested that metabolism of Cr VI by glutathione and cytochrome 
P-450 was required for DNA damage to occur. 
Appenroth and Braunlich (49) reported that in rats given Cr VI subcutaneously, the 
predominant site of renal injury was the tubule, although at the peak of damage there was 
additional glomerular disturbance. The highest tissue concentrations of Cr are seen in the 
renal cortex of animals exposed to Cr VI (Tables I & II). Ellis et al. (17) reported the autopsy 
findings of a 22 month old infant dying 12 hours after Cr VI ingestion, the histological 
changes of acute tubular necrosis were seen and the renal tissue concentration of Cr was 51,9 
mg/kg. It has been postulated that high renal Cr concentrations result from tubular 
reabsorption of Cr (42). However Collins et al. (33) reported in the dog that intra-venous Cr 
VI was rapidly reduced in-vivo and appeared in urine only in the Cr III state and renal tissue 
concentrations of Cr are much lower in animals exposed to Cr III than those exposed to Cr 
VI (Tables I & II, p16 ). Ruegg et al.(41) demonstrated in slices of rabbit renal cortex, that the 
cells of the convoluted proximal tubule were particularly sensitive to Cr VI. The sensitivity 
of these metabolically active cells to Cr VI may be the result of an uptake-reduction process 
similar to that seen in hepatocytes. Besides the direct toxic effect of Cr VI on renal cells, 
patients with Cr VI poisoning may have other additive factors predisposing to acute tubular 
necrosis such as jaundice, blood loss, hypotension, haemolysis and infection. 
The red cell intracellular reactions with Cr VI were discussed above (Transport of Cr). 
It was shown that at high Cr VI levels glutathione reductase was reduced and 
methaemoglobin increased, such cells have a reduced intravascular survival. Sharma et al. (16) 
reported a case of intravascular haemolysis in an 18 year old following Cr VI ingestion. 
Reticulocytosis, anaemia and hyperbilirubinaemia suggestive of haemolysis were noted in a 
case of Cr VI poisoning reported by Fristedt et al. (12). 
Diarrhoea and vomiting are universally present in Cr VI poisoning and have been 
attributed to the known mucosa! irritant properties of Cr VI. There has been only one case 
reported of Cr VI taken intravenously (21) and interestingly, nausea, vomiting and bloody 
diarrhoea were early clinical features. In case 7 reported below, severe colonic necrosis was 
seen at autopsy following oral ingestion of Cr VI, and in another 4 cases haematemesis was 
reported following rectal Cr VI. Intestinal mucosa may be damaged directly by intraluminal 
Cr VI and by blood-borne Cr VI. 
CASE PRESENTATIONS 
The following patients were all in-patients of Groote Schuur Hospital, Cape Town. 
between December 1979 to January 1990 and were referred to the Renal Unit of the 
Department of Medicine with unexplained acute renal failure. All patients were subsequently 
shown to have acute hexavalent chromium poisoning. 
CASE 1 (N.M.) 
This previously well 41yr old black male, a packer for a local company presented on 
22/5/89 three days after self administration of an enema. The enema consisted of a cup of 
orange-red liquid which had been purchased from a township traditional healer as a purgative. 
He had been warned to expect some diarrhoea and vomiting. Soon after taking the enema 
there was the onset of diarrhoea initially orange-red liquid and subsequently frank blood 
mixed with a little stool. This was followed by vomiting of "coffee grounds", severe colicky 
abdominal pain and profound muscle weakness. Prior to admission he noted he was passing 
diminishing quantities of urine and developed dysphagia and hiccoughs. 
EXAMINATION 
General : Sick looking man, jaundiced, not anaemic, apyrexial, with generalised muscle 
tenderness, no oedema. 
C.V.S. : Pulse 64/min, B.P. 150/80, Venous pressure 4cm, Heart sounds normal. 
R.S. : Chest clear except a few fine crackles at both bases. 
G.I.T. : Marked epigastric and right upper quadrant tenderness. No organomegaly. Stool 
occult-blood positive. 
C.N.S. : Normal. Funduscopy normal. 
INVESTIGATIONS 
URINE : S.G. 1,010, Protein 2+, Blood 2+. Microscopy - Red and white cells 3+, broad 
granular casts and debris 4 +. 
C.X.R.: Normal. 
AX.R. : Normal. 
E.C.G. : Normal. 
Renal ultrasound: Normal sized kidneys, no obstruction. 
HAEMATOLOGY: Hb.15,8gm/dl, HCT.0,48, MCV.87£1, WCC.12,3 Prothrombin INR.2,5. 
BIOCHEMISTRY: Sodium 128mmol/l, Potassium 4,6mmol/l, Urea 27,8mmol/l, Creatinine 
847micro-mol/l, Protein 74gm/l, Albumin 40gm/l, Calcium 2.13mmol/l, Phosphate 
2,64mmol/l, Cholesterol 4, 7mmol/l, Total bilirubin 42micro-mol/l, Conj.bilirubin 29micro-
mol/1, Alk. Phos.169u/1, AST.1600u/l, ALT.2650u/L, CPK357u/l, LDH.1967u/l. 
LDH.isoenzymes - LD 1 and 2 raised suggestive of intra-vascular haemolysis. LD 5 raised 
suggestive of hepatic or skeletal muscle damage. Blood digoxin level 1,4nmol/l. 
ASSESSMENT AND MANAGEMENT 
The patient provided us with a sample of the enema and this was shown to contain 
high levels of dichromate together with a digoxin-like substance. Subsequently therapeutic 
levels of digoxin and toxic levels of chromium were found in his blood. He was assessed as 
having acute renal failure as a result of dichromate induced tubular necrosis and required 
haemodialysis for 14 days. He remained oliguric until 1/6/89 when he began to pass 
increasing quantities of urine. The relatively elevated creatinine together with muscle 
tenderness raised the possibility of rhabdomyolysis however the CPK was only modestly 
raised and the LDH. isoenzyme pattern was not specific for muscle injury in the presence of 
such deranged liver enzymes. His hepatitis as evident by the raised enzymes and prolonged 
INR. settled with time and was not a clinical problem. Although intravascular haemolysis has 
been reported with dichromate poisoning and this patient had LDH.isoenzymes LD 1 and 2 
raised, he maintained his haemoglobin with no increase in reticulocyte count. This patient 




CHROMIUM : ATOMIC ABSORPTION SPECTROMETRY RESULTS (Case 1) 
ENEMA FLUID : 6,250 mg/1 (6,25 gm/1) 
BLOOD & URINE : Day 2 - Whole blood pre-dialysis 3, 7 mg/1 
Whole blood post-dialysis 4,0 mg/1 
Urine 5,4 mg/1 
Day 6 - Whole blood 2,0 mg/1 
Day 18 - Whole blood 1, 1 mg/1 
Urine 0,03 mg/1 
CASE 2 (E.D.) 
This 27 yr old black male labourer was admitted to another hospital on 23/11/79 with 
epigastric pain and haematemesis. He was noted to be oliguric and in renal failure. His 
haemoglobin dropped from 12 to 9gm/dl over ten days. He failed to respond to diuretics, 
became increasingly dyspnoeic and was transferred to this hospital on 3/12/79 in coma. The 
patient's uncle gave a history that two weeks prior to admission the patient had complained 
of low back pain and self-administered an enema made from an orange powder obtained from 
a local herbalist. Shortly afterwards he became ill and developed diarrhoea and vomiting. 
EXAMINATION 
General : Critically ill, pale, with a uraemic fetor, in coma, responding to painful stimuli only. 
C.V.S.: Pulse 98/min, B.P. 100/70, J.V.P. 6cm, Gallop rhythm, peripheral oedema+. 
R.S. : Tachypnoeic with bilateral crackles and wheezes. 
G.I.T. : Normal. 
C.N.S. : Encephalopathic but with no localising neurological deficit. Funduscopy normal. 
INVESTIGATIONS 
URINE : Protein 2 +, Blood 2 +. Microscopy : numerous red cells, occasional white cells and 
casts (granular and white-cell). Urinary protein 0,67 gm/1 (2.10gm/24hr ). Chromium 0,5mg/I. 
C.X.R. : Normal sized heart with bilateral pulmonary oedema. 
HAEMATOLOGY: Hb 9gm/dl. 
BIOCHEMISTRY : Sodium 143mmol/l, Potassium 3,5mmol/l, Urea 82mmol/l, Creatinine 
2650micro-mol/l, Protein 62gm/l, Albumin 31gm/l, Calcium 1.96mmol/1, Phosphate 
1,96mmol/l, Urate > 0.80mmol/l, Total bilirubin 12 micro-mol/1, Conj.bilirubin 8 micro-mol/1, 
Alk. Phos.370u/l, AST.> 300u/1. Chromium 2, 7mg/I. 
ASSESSMENT AND MANAGEMENT 
On admission this patient presented a clinical picture of acute renal failure with toxic 
encephalopathy and pulmonary oedema. Toxin ingestion was suspected and confirmed when 
the patient's uncle brought in some orange crystals which had been received as a herbal 
medicine. Analysis of this substance revealed it to be potassium dichromate and subsequent 
analysis of blood and urine confirmed toxic levels of chromium. After recovery the patient 
admitted having given himself a rectal enema of a solution of these crystals. On admission 
peritoneal dialysis was commenced and continued for 12 days with improvement in his mental 
state and pulmonary oedema. During this phase of his illness he was polyuric. At follow up 
4 months later his urea and creatinine were in the normal range (urea 4,7mmol/l, creatinine 
107micro-mol/l) and he had no serious sequelae from his illness. 
CASE 3 (F.M.) 
This 30yr old black male presented to his local Day Hospital on the 14/7 /89 and was 
referred on to this hospital. His background history was that he was a married man with two 
children and employed as a storeman at a local retail store. There was no prior medical 
history of note and he had been completely well until one week before admission when he 
developed an evening headache. He took two proprietary analgesics and subsequently after 
his evening meal developed severe diarrhoea. This was initially dark black in colour but after 
three days he noted frank blood mixed with the stool. There was associated vomiting, initially 
of bile-stained vomitus and later of "coffee-ground" material. For three days before admission 
he had suffered constant epigastric pain which radiated through to his back, and had noted 
that his urine output was very scanty. During this period of time he consulted two general 
practitioners and received symptomatic treatment. He was asked directly about traditional 
remedies and denied either consulting a traditional healer or taking any other medication. 
EXAMINATION 
General : Sick looking man with a uraemic fetor, and frequent hiccoughing. Apyrexial with 
no pallor, adenopathy, clubbing, jaundice nor oedema. 
C.V.S. : Pulse 90/min full volume, B.P. 160/100, Venous pressure not elevated, Apex beat not 
displaced and Cardiac auscultation normal. 
R.S. : Increased rate and depth of respiration. Lungs clear. 
G.I.T. : Soft, no organomegaly, bowel sounds present, with some epigastric tenderness. Rectal 
examination revealed soft brown stool which tested positive for occult blood. 
C.N.S. : Normal. Funduscopy normal. 
INVESTIGATIONS 
URINE : Dipstix- S.G.1,010, Protein 2+, Blood trace. Microscopy- Leucocytes 3+, occasional 
hyaline and granular casts, debris 3 +. 
C.X.R. : No cardiomegaly, clear lung fields. 
E.C.G. : Sinus rhythm at 75/minute, PR.interval 0,14 sec, QRS.axis + 10, Left ventricular 
hypertrophy on voltage criteria. 
Renal ultrasound: No obstruction but increased parenchymal echogenicity. Kidney size - right 
11,8cm and left 11,6cm 
HAEMATOLOGY: Hb. 15,6gm/dl, HCT. 0,41, MCV. 83,3, RBC. morphology normal. PLT. 
296,0, WCC. 11,28. Differential - neutrophils 74%, lymphocytes 15%, monocytes 8%, 
eosinophils 1%, large unstained cells 2%. Westergren sedimentation rate 32mm/hr. 
Prothrombin INR. 0,9. 
BIOCHEMISTRY : Sodium 123mmol/l, Potassium 5mmol/l, Urea 53,4mmol/l, Creatinine 
1552micro-mol/l, Glucose 5,2mmol/1, Protein 68gm/l, Albumin 39gm/l, Calcium 2,18mmol/l, 
Cholesterol 6,7mmol/l, Urate 0,92mmol/l, Total bilirubin 5micro-mol/l, Conj. bilirubin 
2micro-mol/l, LDH.(kinetic) 623u/l, AST. 44u/l, ALT.31u/L, Gamma GT. 45u/1, Amylase 
268u/1. 
ASSESSMENT AND MANAGEMENT 
This man was assessed as being in acute renal failure due to acute tubular necrosis 
secondary to severe gastroenteritis and dehydration. Haemodialysis was commenced using 
minimal heparin in view of the history of gastrointestinal bleeding. Haemodialysis was 
continued for five days together with careful fluid and electrolyte management. Urine output 
increased and renal function improved, at follow-up six weeks later his serum urea was 5 
mmol/1 and creatinine 76 micro-mol/1. During his admission, following direct questioning he 
admitted visiting a local township Sangoma (traditional healer). On the day following the 
onset of headache he consulted the Sangoma, who mixed an enema in a tin can from a variety 
of ingredients in his consulting room and administered it rectally by means of rubber tubing. 
The charge for this consultation was R90. Within minutes of insertion of the enema there was 
onset of profuse diarrhoea and vomiting. Later he noted the stool to be plum coloured and 
the vomitus to be like "coffee grounds". Although the enema fluid was not available for 
analysis the diagnosis of hexavalent chromium poisoning was confirmed by the demonstration 
of toxic levels of chromium in both blood and urine. The urinary chromium concentrations 
and total daily excretion are given below together with blood and dialysate values. 
TABLE IV 
CHROMIUM : ATOMIC ABSORPTION SPECTROMETRY RESULTS.(Case 3) 







24 hr VOL. Cr Cone. 
1550 ml 2,1 mg/1 
1200 ml 1,5 mg/1 
1530 ml 3,5 mg/1 
980 ml 0,75 mg/1 
1580 ml 0,45 mg/1 
24 hr Vol = 24 hour urine volume. 
Cr cone. = Chromium concentration mg/1. 
Total Cr = Total 24 hour urinary Chromium. 
WHOLE BLOOD CHROMIUM LEVELS 
Day 1 = 2,5 mg/1 
Day 4 = 2,3 mg/1 





























Art. = Blood line leading to dialysis membrane. 
V. = Blood line leading from dialysis membrane. 









Values represent red cell, plasma and whole blood chromium concentrations in mg/1. at the 
commencement and at the end of 4 hours of dialysis. Day 3 was the third day of 
hospitalisation, 17 /7 /89 and was the second dialysis performed. Day 4 was the 18/7 /89 and 
Day 5 the 19/7 /89. 
CASE 4 (V.S.) 
A 47yr old mother of nine who worked as a domestic worker at City Park Hospital 
presented on the 27 /12/87 with a 7 day history of bloody diarrhoea, with associated colicky 
central abdominal pain which was relieved by defaecation. She suffered from chronic 
constipation using laxatives regularly and had consulted a traditional healer for this problem. 
He had prescribed a yellow liquid and it was after the self-administration of about 50ml of this 
solution that her symptoms of vomiting and diarrhoea had started. Prior to admission she had 
noted the development of oliguria. 
EXAMINATION 
General : Apyrexial, no jaundice, no anaemia. 
C.V.S.: Pulse 110/min, Venous pressure not elevated, B.P. 130/85 with no postural drop. 
R.S.: Normal. 
G.I.T. : Diffuse abdominal tenderness, no organomegaly, blood and mucus on rectal 
examination. Sigmoidoscopy : no ulceration but erythematous mucosa with small 
haemorrhages and contact bleeding. 
C.N.S. : Fully alert with no neurological deficit. 
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INVESTIGATIONS 
URINE : S.G. 1,010, Blood trace, Protein +. Microscopy - 5 wbc/hpf, numerous granular casts 
and debris. Urinary Electrolytes - Osmolality 227mosm/1, Sodium 60mmol/1, Potassium 
18mmol/l, Urea 10,7mmol/l, Creatinine l,9mmol/l. 
C.X.R.: Normal. 
Renal ultrasound: Both kidneys 14 cm, No obstruction. 
HAEMATOLOGY: Hb ll,6gm/dl, wee. 14,2, PLT. 403. 
BIOCHEMISTRY : Sodium 107mmol/l, Potassium 5,8mmol/l, Urea 45mmol/l, Creatinine 
1355micro-mol/l, Glucose 3,7mmol/l, Albumin 27gm/l, Calcium 1,48mmol/l, Phosphate 
2,59mmol/l, Total bilirubin 7micro-mol/l, Conj. 2micro-mol/l, Alk. Phos. 115u/l, LDH.1148u/l 
(Isoenzymes LDH.1 AND 2), AST. 21u/l, ALT. 107u/l, GGT. 63u/l. Venous gases: pH 7,3, 
pC02 3,7kp, p02 5,7kp, Base excess -11,8, 
ASSESSMENT AND MANAGEMENT 
Due to the initial uncertainty of diagnosis a renal biopsy was performed which showed 
changes of acute tubular necrosis with tubular regeneration and a patchy interstitial infiltrate 
of polymorphs, lymphocytes and plasma cells. Subsequent analysis of the enema fluid revealed 
a high concentration of sodium dichromate (Chromium content by AAS. 40gm/l). The patient 
was assessed as having dichromate induced acute tubular necrosis and required haemodialysis 
until 13/1/88 (17 days). Inspite of good urine output, the slow rate of recovery of renal 
function was felt to be a bad prognostic sign and at follow up 24 months later significant renal 
impairment was still present (Urea 9mmol/l and Creatinine 155micro-mol/l). The elevated 
LDH. together with the isoenzyme pattern were suggestive of haemolysis and the 
haemoglobin subsequently fell to 6,5gm/ dl, requiring a transfusion of three units of packed 
cells on 13/1/88. Abdominal symptoms and liver function tests rapidly normalised. 
Attempts to contact the prescriber of the enema were unsuccessful and the patient 
refused to bear witness against him. 
CASE 5 (J.N.) 
This 37yr old black male presented to this hospital on the 2/11/89 four days after the 
self administration of an enema. He admitted to being a regular user of such enemas, this one 
having been purchased from a township traditional healer. Immediately post administration 
he experienced the acute onset of severe burning lower abdominal pain followed by bloody 
diarrhoea and vomiting. The diarrhoea continued until the day before admission when the 
stool became yellow and mucoid. He reported that he had been totally anuric for 36hrs and 
his admission was precipitated by exacerbation of the abdominal pain. 
EXAMINATION 
General : Alert and fully orientated. Apyrexial, no jaundice, pallor nor oedema. 
C.V.S. : Pulse 100/min, B.P. 170/95, Venous pressure not elevated, Cardiac auscultation 
normal. 
R.S. : Normal 
G.I.T. : Diffuse tenderness, bowel-sounds present, generalised peritonism with rebound 
tenderness. Rectal examination revealed yellow mucoid stool which tested positive for occult 
blood. 
C.N.S.: No neurological deficit. Funduscopy normal. 
INVESTIGATIONS 
URINE: Not available. 
C.X.R. : No cardiomegaly, clear lung fields. 
AX.R. : Non specific ileus pattern and no free gas. 
HAEMATOLOGY: Hb. 13,7gm/dl, HCT. 0,36, MCV. 83fl, PLT. 153, wee. 16,16. 
BIOCHEMISTRY: Sodium 128mmol/l, Potassium 5,lmmol/1, Urea 49,5mmol/l, Creatinine 
1115micro-mol/l, Protein 50gm/l, Albumin 27gm/l, Calcium 1,83mmol/l, Phosphate 
2,02mmol/l, Cholesterol 3,5mmol/l, Urate 0,58mmol/l, Total bilirubin 14micro-mol/l, Alk. phos 
118u/l, LDH.980u/l, AST. 18,u/l, ALT. 65u/l, GGT. 35u/l. 
ASSESSMENT AND MANAGEMENT 
This man was suspected of having taken a dichromate containing enema and this was 
confirmed by finding toxic levels of chromium in his blood. His renal failure was managed by 
fluid and electrolyte restriction together with haemodialysis. Dialysis was performed via 
bilateral femoral vein catheters with minimal heparin use. Urine output improved over the 
following days and dialysis was discontinued on day ten. At follow-up two months later the 
urea and creatinine had returned to normal levels. His abdominal pain and diarrhoea were 
slow to settle, and he required a transfusion of two units of packed cells on the 6/11/89. 
The urinary chromium excretion together with blood and dialysis data are given below. 
TABLE VI ATOMIC ABSORPTION SPECTROMETRY RESULTS (CASE 5) 
Day 1 Start of dialysis. 
BLOOD 6* mg/1 
PLASMA 3,4 mg/1 
PLASMA WATER 2,6 mg/1 
DIALYSATE 0,1 mg/1 
Day2 
BLOOD 4* mg/1 
PLASMA 2,8 mg/1 
PLASMA WATER 1,17 mg/1 
DIALYSATE 0,07 mg/1 









Values represent Chromium concentrations at the start of haemodialysis and at the end of 
2 hours of dialysis on Day 1 (2/11/89) and 4 hours on Day 2 (3/11/89). Plasma water is the 
ultra-filtrate of plasma using a Baxter 15:11 hollow fibre membrane. * There were technical 
problems ashing these samples. 
URINARY CHROMIUM EXCRETION 
Day 24 hr Vol. Cr cone. 
5 220 ml 12,5 mg/1 
6 305 ml 11,3 mg/1 
7 1440 ml 5,8 mg/1 
8 1650 ml 5,6 mg/1 
9 2000 ml 4,7 mg/1 
Cr cone. = Chromium concentration mg/1. 







CASE 6 (D.M.) 
This 22yr old black male was previously quite well and attending school in Transkei 
when in February 1989 he developed episodes of psychotic behavior. This prompted his 
mother to bring him to Cape Town where his father was employed and they placed their son 
in the care of a local township traditional healer. Whilst under his care, he was given an 
enema which evidently caused some rectal trauma as he recalls passing blood but no stool. 
Over the next few days he was given oral medicines which resulted in profuse diarrhoea and 
his subsequent admission to this hospital on the 8/8/89. 
EXAMINATION 
General : Toxic looking young man, dehydrated, hypothermic, shocked and unable to give an 
account of himself. Ulcerations involving the corners of the mouth and the buccal mucosa 
extending to the pharynx. The ulcers were noted to have dry looking leathery bases. The 
tongue was inflamed and swollen. 
C.V.S.: Pulse 96/min, B.P. 120/70, Heart sounds normal. 
R.S. : Acidotic breathing. Lung fields clear. 
G.I.T. : Soft, no organomegaly. Posterior to the anus there was an area of skin necrosis and 
there was an offensive discharge. 
C.N.S. : Confused but with no localising neurological deficit. Tendon reflexes were brisk 
bilaterally. 
INVESTIGATIONS 
URINE: Microscopy - Red cells 3+, broad granular casts and debris. 
C.X.R.: Normal. 
AX.R. : Dilated small loops of bowel, no obvious obstruction. 
HAEMATOLOGY: Hb. 9,2gm/dl, WCC. 53,000, PLT. 316, Prothrombin INR. 1,3, PTT. 28. 
BIOCHEMISTRY : Sodium 114mmol/l, Potassium 5,4mmol/l, Chloride 80mmol/l, Urea 
82,8mmol/l, Creatinine llOOmicro-mol/1, Protein 60gm/l, Albumin 26gm/l, Calcium 
1, 73mmol/l, Phosphate 2,53mmol/l, Cholesterol 3,9mmol/l, Orate 0,94mmol/l, Total bilirubin 
9micro-mol/l, Conj.bilirubin 2 micro-mol/1. Kinetic Enzymes - CPK1324u/l, LDH.1004u/l, 
AST. 40u/l, ALT. 8u/l. Blood gases - pH7.13, pC02 1,8kp, p02 20kp, Base excess -23, 
Standard bicarbonate 7 ,4. 
BACTERIOLOGY : Blood cultures positive for Streptococcus pneumomae and Proteus 
mirabilis. 
ASSESSMENT AND MANAGEMENT 
After initial resuscitation he became polyuric, and was assessed as being septicaemic 
in non-oliguric renal failure with a severe metabolic acidosis. Haemodialysis was required for 
the first week, although he never became anuric. His blood urea and creatinine levels steadily 
improved, normalising about 8 weeks after admission. Initial management included broad 
spectrum antibiotics, ventilation and parenteral nutrition. This patient required multiple 
surgical procedures. On 30/7 /89 an area of necrotic skin 4 cm by 2 cm posterior to the anus 
was debrided and a necrotising fasciitis-like slough was found to extend upwards between the 
rectum and sacrum as far as the sacral promontory, requiring extensive tissue excision 
including the levator ani muscles. A perforation of the posterior anal canal was noted, and a 
defunctioning colostomy was performed. Three days later a second debridement was carried 
out when further necrotic tissue was excised from the retroperitoneal area of the pelvis. Two 
major haemorrhages occurred from the pelvic cavity which required suture ligation of the 
bleeding vessels. 
Blood chromium level was elevated in the toxic range (3,0 mg/I). It was presumed that 
this patient had an enema which damaged the rectum with possible extravasation of enema 
contents complicated by further necrotising fasciitis from secondary infection. He most likely 
was also given dichromate orally causing the oropharyngeal ulceration and diarrhoea, with the· 
absorbed hexavalent chromium being an additive causative factor in the development of acute 
tubular necrosis. 
He was left with impaired bladder control; without sensation of bladder filling and no 
control over urination. A cysto-metrogram showed features of both an upper and lower motor 
neurone bladder. This has been managed by intermittent self catheterisation. The pelvic 
wound was slow to heal and he has been left with a permanent colostomy. Neurological 
assessment failed to find any cause for his initial neurological condition and there were no 
further episodes of psychotic behavior. There was full recovery of the oral ulceration, and 
renal dysfunction resolved. 
CASE 7 (W.P.) 
A 48yr old black male labourer at an explosives factory was treated on the 18/10/85 
at the company hospital with parenteral penicillin for gonorrhoea. One week later he was 
admitted to the same hospital with diffuse abdominal pain, bloody diarrhoea, vomiting and 
oliguria. On admission he was noted to be pyrexial, jaundiced and anuric. It was known that 
he had taken a traditional remedy for venereal disease immediately prior to admission, taking 
this medicine orally rather than as an enema or topical application. The medicine had been 
purchased in Guguletu earlier for R50. He was transferred to this hospital on the 28/10/85 
and the medication was sent along with him. It was an oily liquid with an orange hue which 
turned green on the addition of acid ; bench-top analysis demonstrated a high concentration 
of dichromate and potassium in the mixture. 
EXAMINATION 
General : Distressed, markedly jaundiced, apyrexial and no pallor nor oedema. 
C.V.S.: Pulse 100/min, B.P. 115/70, Venous pressure 5cm, Heart sounds normal with a 2/6 
ejection systolic murmur. 
R.S. : Normal. 
G.I.T. : 8cm tender hepatomegaly, additional lower abdominal tenderness, stool occult-blood 
positive. 
C.N.S.: No abnormality. Funduscopy normal. 
INVESTIGATIONS 
URINE: Not available. 
C.X.R. : No cardiomegaly, clear lung fields. 
AX.R. : Dilated loops of small bowel with multiple fluid levels and a right upper quadrant 
mass consistent with an enlarged liver. 
E.C.G. : Normal. 
Renal ultrasound: Normal sized kidneys with increased echogenicity. 
HAEMATOLOGY : Hb. ll,6gm/dl, HCT. 0,35, MCV.77, PLT. 213, WCC. 9,3. Differential 
normal with no left shift. Prothrombin INR. 2,3. 
BIOCHEMISTRY : Sodium 121mmol/l, Potassium 6mmol/l, Urea 40mmol/l, Creatinine 
986micro-mol/l, Bicarbonate 12mmol/l, Protein 70gm/l, Albumim 31gm/l, Calcium 
l,78mmol/l, Phosphate 4,03mmol/l, Urate 0,85mmol/l, Total bilirubin 171 micro-mol/1, Conj. 
142micro-mol/l, Alk Phos. 205u/l, LDH. 2740u/l. 
GASTROSCOPY : Oesophagitis with friable necrotic tissue but no active bleeding and no 
varices. There were petechial haemorrhages in the stomach with contact bleeding. No peptic 
ulcer seen. 
SIGMOIDOSCOPY : Normal. 
BACTERIOLOGY : Viral screen (incl. Hep B, VDRL.) negative. Blood cultures and 
Leptospirosis serology negative. 
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ASSESSMENT AND MANAGEMENT 
This man was assessed as being in oliguric acute renal failure together with 
hepatic failure and gastro-intestinal necrosis secondary to oral dichromate ingestion. 
Peritoneal dialysis was commenced but discontinued because of technical problems. Daily 
haemodialysis via bilateral femoral vein catheters was started on day 4 (31/10/85) and 
continued until day 24 (20/11/85). Charcoal haemoperfusion was performed on days 6,7,and 
8. Liver failure was treated with Lactulose, oral neomycin and parenteral vitamin K In view 
of his gastro-intestinal pathology he was kept nil by mouth and parenteral nutrition was 
commenced on day 3. On day 3 intubation and ventilation were required because of 
deteriorating respiratory function. Initially he was haemodynamically stable, however from 
day 5 onwards he developed increasing rectal blood loss. The stool was maroon in colour and 
two to four units of blood were required daily to maintain his haemoglobin. The patient 
remained lucid and conscious, his jaundice resolved and hepatic function improved although 
gastrointestinal blood loss continued. On day 10 hyperglycaemia was noted and Candida 
albicans was cultured from blood, urine, and stool. Cultures remained positive despite 
parenteral amphotericin B. Following a large haematemesis on day 23, a repeat gastroscopy 
showed an erosive oesophagitis with active bleeding. A Sengstaken balloon was used but failed 
to control the bleeding. The following day (29/11/85) the patient became bradycardic and 
died. 
POST MORTEM FINDINGS 
There were extensive changes in the gastrointestinal tract with erosions and necrosis 
of the oesophageal mucosa, gastritis and mucosal desquamation and necrosis throughout the 
colon. The kidneys were large and pale, with numerous small cortical abscesses filled with 
Candida, and there was evidence of widespread tubular damage. The liver was homogeneously 
enlarged. Because of considerable autolysis further histological analysis was not performed. 
Analyses of the chromium content of the traditional medicine, blood samples and post mortem 
tissues are given below. 
TABLE VII 
ATOMIC ABSORPTION SPECTROMETRY RESULTS (Case 7) 
ADMISSION RESULTS. 
Whole Blood Chromium : 2,0 mg/1 
Serum Chromium : 0,4 mg/1 
Urine Chromium : 2,0 mg/1 
SERUM CHROMIUM CONCENTRATIONS. 
Day 1 0,4 mg/1 
Day2 0,5 mg/1 
Day9 0,4 mg/1 
Day 12: 0,5 mg/1 
Day 17: 0,4 mg/1 
Day 19: 0,3 mg/1 
POST MORTEM CHROMIUM ANALYSIS. 
ORGAN CHROMIUM CONC. TOTAL CHROMIUM 
Liver 45,0 mg/kg 96mg 
Kidney 10,0 mg/kg 5mg 
Stomach 3mg 
Intestine 0,3 mg/kg 4mg 
Brain 0,3 mg/kg 2mg 
CASE DISCUSSION 
Complications following tradition enema usage have been documented in a series 
reported from Baragwanath Hospital (44). Of their 11 reported cases, 2 (one suspected and 
one definite) followed the use of dichromate containing enemas. Both of these patients 
suffered gastrointestinal mucosal ulceration, however renal failure and hepatic dysfunction 
were not reported features. In each of the 7 cases documented above, the clinical features 
were compatible with the known toxic effects of acute dichromate poisoning, blood chromium 
levels were demonstrated well into the toxic range and where the medication administered 
was available, dichromate was in high concentration and the major active ingredient. All our 
patients were young black adults with an age range from 22 - 48 years (mean age 36 yrs), and 
there was only one female (case 4). Six patients took the medication as an enema, one orally 
(case 7), and one appeared to have been given both oral and rectal medication (case 6). The 
delay between taking the medication and presentation at hospital was from 3 and 7 days in 
all patients except case 7, who was reported to have taken oral medication immediately before 
hospitalisation. All our patients had renal failure but there was also a markedly variable 
pattern of hepatic and gastrointestinal involvement. At presentation all gave a history of 
abdominal pain, gastro-intestinal haemorrhage and oliguria. In cases 2, 3, and 4, the abdominal 
symptoms had largely resolved and the clinical picture was of unexplained acute renal failure. 
In cases 5, and 6, abdominal symptoms predominated, in case 1 there was hepatic failure, and 
in case 7 all three organ systems were involved. 
All the cases (except case 6 who was non oliguric) presented with acute oliguric renal 
failure requiring dialysis. Dialysis was performed for between 7 and 26 days, the length of this 
period being determined by the clinical status of the patient and the rate of recovery of renal 
function. The urine findings were consistent with a diagnosis of acute tubular necrosis, as was 
the renal histology in case 4. Other factors predisposing to acute tubular necrosis were 
present in 3 patients, including sepsis, dehydration and jaundice. The serum creatinines 
before dialysis were very much higher (range 847 - 2650 micro-mol/1) than usual in patients 
with acute renal failure of only a few days duration, an observation that has been previously 
noted in Cr VI toxicity (21). This is suggestive of, 1: acute on chronic renal failure, 2: 
rhabdomyolysis or 3: a hypercatabolic state. Lack of the clinical stigmata of chronic renal 
disease together with recovery of function would exclude chronic renal failure. 
Rhabdomyolysis has not been described in animals exposed experimentally to Cr VI, and 
muscle tissue does not accumulate Cr (25). In cases 1 and 6 serum creatine phosphokinase 
(CPK.) levels were markedly elevated at 357u/l and 1324u/l respectively. The local muscle 
necrosis in the rectal lesion of case 6 would adequately account for his elevated CPK. On the 
other hand in case 1, the presenting symptoms of profound muscle weakness together with 
some muscle tenderness are more suggestive of a myopathic element. This still does not 
necessarily implicate Cr VI as a causative factor, as other metabolic derangements can 
predispose to rhabdomyolysis, such as hypokalaemia and hypomagnesaemia following 
extensive vomiting and diarrhoea. In all the cases, although the serum creatinines were very 
high they were not disproportionate to the serum ureas as would be expected in 
rhabdomyolysis. It is most probable that these patients were very hypercatabolic. Acute 
haemodialysis of patients with Cr poisoning usually poses no significant problems except 
cognisance must be taken of the possibility of exacerbating gastrointestinal haemorrhage if 
heparin is used to prevent clotting on the dialyser membrane. This can be avoided by using 
no or minimal heparin and maintaining high flows across the dialysis membrane via bilateral 
femoral vein catheters. Peritoneal dialysis is a viable alternative. 
Hepatic involvement was particularly variable with two of the patients presenting with 
jaundice, markedly raised transaminases and very prolonged prothrombin times, whilst three 
other patients had near normal transaminases and bilirubin values. Bader (21) reported 
normal transaminases in a patient following intravenous chromic acid and postulated that this 
may have been due to absence of a first highly concentrated pass though the portacaval 
system. Transaminase values after oral ingestion of Cr VI have varied from normal (16), to 
mildly elevated (17,20) and up to levels of AST. and ALT. of 4400u/l (14). In our cases 
bilirubin values paralleled those of the transaminase levels. Alkaline Phosphatase levels were 
mildly elevated in all cases when measured (6 cases). The maximal derangement of liver 
function tests was at the time of admission, with subsequent normalisation in every case. This 
is compatible with a single toxic insult at the time of Cr VI ingestion. The variable 
susceptibility to hepatic injury has not been previously addressed. The first-pass phenomenon 
may indeed be a significant factor, Visek et al. (Table 1) showed a lower liver concentration 
of Cr relative to the kidney after intravenous Cr VI than did Danielsson et al. after 
intraperitoneal Cr VI (Table 2). However all our patients took Cr VI via the gut, and would 
have been exposed to high portal vein concentrations. It could be postulated that the rate of 
absorption was variable, thus exposing the liver to lower portal vein Cr VI concentrations, and 
allowing greater uptake by red cells. Red cells are competing for the Cr VI in the portal vein, 
however the rate of uptake has been shown by Mollison and Veall (35) to be independent of 
Cr VI concentration, within the range of 0,25 -lOmg/1. Another interesting hypothesis could 
be that the variable hepatic injury results from differing activity of intracellular hepatic 
enzymes such as P-450 and glutathione reductase, the in vivo parallel to the in vitro studies 
of Cupo and Wetterhahn (46,47). 
LDH. values were universally raised, and in case 1, iso-enzymes were of haematological 
and liver or muscle origin. In case 4 the iso-enzyme pattern was suggestive of a haematological 
source. In the clinical situation of liver, renal, gut and possible red cell injury, iso-enzyme 
patterns are difficult to interpret. 
Gastrointestinal symptoms were present in all our cases, and was the precipitating 
cause of the death of case 7. M ucosal inflammation and ulceration of the respiratory tract has 
been reported after occupational exposure to Cr VI (5). The extensive necrosis seen at post 
mortem in case 7 was surprising. Even though the Cr VI had been taken orally 41 days 
previously, the colon had mucosal sloughing and necrosis throughout its length. This finding 
together with the universal presence of upper gastrointestinal pathology following rectal Cr 
VI raises the possibility of intestinal mucosal damage from blood-borne Cr VI. 
In none of our cases did the plain abdominal radiographs show either a nephrogram 
or barium enema pattern which has been reported to occur in dichromate poisoning (personal 
communication Professor J.Milne). 
With the incorporation of a toxic substance such as potassium dichromate in commonly 
used purgatives, it might be expected that larger numbers of patients should be presenting 
in renal failure. There are probably several explanations why this is not so. Firstly hexavalent 
chromium is probably detoxified to the trivalent form by organic material mixed in some of 
the enemas. Secondly patients are only recognised as having Cr VI poisoning if the attending 
medical staff have a high index of suspicion, and many cases may pass undiagnosed. Thirdly 
some cases of unexplained death are the result of Cr VI toxicity as demonstrated in the 
forensic data (page 64). 
The presence of significant quantities of a digoxin-like substance in the blood of case 
1 probably resulted from the incorporation of organic material in the enema. Hutchings and 
Terblanche (50) reported the presence of cardiac glycosides in plants of the Hyacinthaceae 
family. This family and others of the superorder Liliiflorae are used in Zulu and Xhosa 
traditional herbal remedies. An alternative explanation may be offered by reports of a digoxin-
like immunoreactive substance noted in the plasma of patients with either liver disease (51) 
or renal failure (52), however this would not explain the presence of a digoxin-like substance 
in the enema fluid itself. 
ANALYSIS METHODS 
Samples including blank and spiked controls were analysed by the same method, which 
entailed firstly, a process of extraction or digestion, followed by atomic absorption analysis. 
The dry ashing technique of digestion required the measurement of 1 ml of liquid or 
1 gm of tissue into a quartz crucible, which was then dried overnight in an oven at 130 deg.C. 
Next morning the remaining sample was ashed in a furnace at 490 deg.C, if the ashing process 
was not complete the sample was redissolved in concentrated nitric acid and reashed. When 
ashing was complete the contents of the crucible were redissolved with 1 ml of concentrated 
nitric acid overnight and after addition of 2,5 mls of distilled water transferred to a centrifuge 
tube. The crucible was repeatedly washed with distilled water, which was added to the 
centrifuge tube until the volume was made up to 10 ml. After centrifugation the supernatant 
was analysed by atomic absorption. 
Atomic absorption analysis ; samples of the prepared solutions were aspirated into a 
reducing air-acetylene flame. The resulting absorbance was measured at a wavelength of 357 ,9 
nm. with a slit width of 0,2 nm .. The calibration range was linear from O - 1,5 ppm. Samples 
above this range were diluted with 10% nitric acid until in range. When solutions were at the 
very low end of the calibration range, 200 ml samples were evaporated and redissolved to a 
volume of 20 ml, to bring them into mid-range. The absorbance of a blank specimen run at 
the same time was subtracted from the absorbance value of the specimen. Three 
measurements of absorbance were taken for each sample and the variation between these 
values was the machine error. In absolute terms this error was very small (0,01 -0,02 ppm.), 
however at very low concentrations such as found in dialysate samples, it may become 
significant. A calibration curve was defined by the use of standard concentrations of 
chromium. Lastly the mean sample absorbance was converted to mg/kg ( ppm.) from the 
calibration curve. Errors may arise from external contamination, loss of sample during 
digestion, machine error, and from a non-linear calibration curve. These errors were 
minimised by 1: careful handling and storage of samples, 2: repeating the digestion process 
and by comparison with the wet ashing process ( boiling samples with cone. nitric acid ), 3: 
adjusting concentration and dilution of samples to keep absorbance in the upper range of 
calibration curve, 4: using the near linear range of the calibration curve. 
CHROMIUM: ATOMIC ABSORPTION SPECTROMETRY RESULTS 
TABLE ill.(p23) The chromium content of the enema fluid was very high, (6,25 mg/1) 
and if it was all present in the Cr VI form, as little as 100 ml would be a potentially lethal 
dose (23). Blood analysis failed to demonstrate any lowering of chromium level after 4 hrs of 
dialysis on day 2. As will be demonstrated later the greater proportion of Cr is in the red cells 
and thus changes in haematocrit alone will significantly affect whole blood chromium levels. 
It would thus be possible to apparently raise whole blood Cr levels by removal of plasma water 
with ultrafiltration during dialysis. The urine concentration of 5,4 mg/1 on day 2 would 
however suggest that some dialysable chromium is present in the blood. This dialysable 
chromium had almost disappeared by day 18 (Urine Cr 0,03 mg/1), whilst the whole blood Cr 
was still significant at 1, 1 mg/1. 
TABLE IV.(p29) Over a 5 day period during the recovery phase of acute tubular 
necrosis 12 mg of chromium were excreted in the urine. This is a small proportion of the total 
body chromium. By day 5 the excretion was less than 1 mg/day despite a whole blood 
concentration of 1,9 mg/1 and recovering renal function. The early diminution of urinary Cr 
excretion would appear to fit well with the observations of Collins et al. who showed in the 
dog, a rapid early fall in dialysable Cr after Cr VI exposure. 
TABLE V.(p30) The conventional measurement of dialysis clearance of a substance 
is made by demonstrating an arterio-venous (A-V) concentration gradient in the blood supply 
to and from the dialyser membrane. The data in this table fails to show any significant A-V 
difference in Cr concentrations during this patients second, third and fourth 4 hr dialysis 
treatments. To attempt to identify an A-V gradient in any of the various blood compartments, 
whole blood, plasma and red cells were analysed separately but no gradient was found. During 
these analyses the wet ashing process appeared unsatisfactory for red cell digestion. The red 
cell to plasma Cr content ratio was approximately 5: 1 which is similar to that reported by 
Fristedt et al.(12). 
TABLE VI.(p36) These data differ from the other preceding tables in that the dialysis 
values of the 2/11/89 are those of the first dialysis received by this patient. During the first 
hour of dialysis there was a significant drop in whole blood Cr. In this study blood samples 
were separated into whole blood, red cells, plasma, and plasma water represented by the 
ultrafiltrate of plasma. At commencement of dialysis the red cell to plasma Cr ratio was only 
2:1. This lower ratio appears to be due to an unusually high plasma Cr, which in turn is the 
result of a very high plasma water Cr. It is this form of Cr that has been postulated to be 
dialysable (33). The decline of plasma water Cr content during the dialysis was paralleled by 
the appearance of Cr in the dialysate. A dialysate concentration of 0,1 mg/1 represents a 
clearance of about 3,0 mg of Cr /hr. A similar trend but to a lesser degree is seen during the 
second dialysis. At the end of dialysis on day 2 the dialysable Cr was 0,3 mg/1, near the limits 
of detection by the methods used in these studies. Total urinary excretion of Cr is a function 
of the dialysable concentration in blood together with the glomerular filtration rate. The 
increase of Cr excretion from 2,8 mg on the 6/11/89 to 9,4 mg on the 12/11/89 does not 
follow the pattern shown by case 3 (Table IV). As there was very little dialysable blood Cr 
present after the second dialysis and this patient was still dialysis dependent it would seem 
that the dialysable Cr may have subsequently risen. One possible hypothesis could be that due 
to red cell destruction intracellular Cr III was being released and subsequently excreted or 
that some other body compartment was releasing Cr. This patient did drop his haemoglobin 
from 13,2 gm/ dl to 7 ,3 gm/1 requiring transfusion of 4 units of packed cells. Another 
interesting hypothesis could be that the citrate in the transfusions acted as a chelating agent 
by solubilising tissue bound Cr and allowing its excretion. 
TABLE VII.(p44) Again the red cell to plasma Cr ratio was shown in this patient to 
be approximately 5: 1 and the urinary Cr was significant on admission at 2,0 mg/1. The serum 
Cr concentration remained almost constant over a period of 20 days, despite repeated dialysis 
and multiple red cell and plasma transfusions. This would suggest a mobilisation of the tissue 
bound Cr into the blood and binding to the plasma proteins. Transferrin can bind Cr more 
readily than other plasma proteins and this binding is blocked in the presence of iron (34). 
If this patients microcytosis represents an iron deficient state it would be interesting to 
postulate that the increased unbound transferrin may allow more rapid mobilisation from the 
tissues. The post mortem tissue analysis confirms the preferential uptake of Cr by 
hepatocytes and renal cells. 
FORENSIC DATA. 
These four post mortem cases were referred to the Forensic Chemical Laboratory of 
the Department of Health and Population Development, Cape Town for toxicological 
screening, between the dates of August 1988 to December 1989. Each was a case of 
unexplained death, which after screening appears to have been the result of Cr VI 
intoxication. Two cases originated from Transkei, one from Ciskei and one from the E. Cape. 
*Case 3 was accompanied by a sample of black medicinal powder thought to have been 
ingested prior to death. On analysis this contained an extremely high concentration of Cr 
Results of Cr analysis are expressed as tissue Cr concentration and also as total organ Cr 
content. Concentrations are in ppm or mg/kg and total content in mgs. 
TABLE VIII 
FORENSIC DATA. 
TISSUE CrCONC. TOTAL Cr 
CASE 1. 
Kidney 5,6 mg/kg 2,8mg 
Liver 16,5 mg/kg 24mg 
CASE 2. 
Kidney 107 mg/kg 78mg 
Liver 61 mg/kg 87 mg 
Stomach 55mg 
CASE 3.* 
Kidney 195 mg/kg 
Liver 530 mg/kg 
Stomach 170 mg/kg 
CASE 4. 
Kidney 73 mg/kg 
Liver 75 mg/kg 
Gall Bladder 53 mg/kg 
Stomach 28 mg/kg 
Duodenum 14 mg/kg 
Blood 23 mg/1 
FORENSIC DATA DISCUSSION. 
Table VIII shows the results of tissue chromium analysis of four post mortems carried 
out on cases of unexplained death. In cases where a toxin is suspected, a toxicology screen is 
performed which includes analysis for drugs, pesticides and metals. The tissue levels of Cr are 
so high that they could only be consistent with Cr VI ingestion. The macroscopic organ 
findings in case 2 were unremarkable except for the observation that the bowel mucosa 
appeared a little injected. This data is interesting in several ways, firstly as these cases came 
from different areas it would appear that the use of Cr VI is widespread. Secondly the 
concentrations in the upper bowel in cases 2, 3, and 4 are suggestive of recent oral ingestion. 
Thirdly the ratio of Cr content between liver and kidney tissue is variable. In Case 1 the liver 
to kidney Cr concentration ratio was 3 to 1 but in case 2 the ratio was 0,6 to 1, demonstrating 
the variable uptake by these two organs. This may be explicable by the hypothesis that the 
induction ofliver enzymes can increase the hepatic uptake of Cr. Alcohol and anti-tuberculous 
drugs are two well recognised enzyme inducers. Lastly the values in cases 2, 3, and 4 are 
considerably higher than any prior published figures. 
TREATMENT OF DICHROMATE POISONING. 
All seven cases documented above, presented to this hospital several days after 
exposure to dichromate and non-specific measures to reduce absorption were not indicated. 
The specific treatment of acute Cr VI poisoning remains unproven being derived from animal 
studies together with infrequent case reports. Three main areas of therapy have been 
advocated : Firstly antidotes given orally to reduce Cr VI in the gut to the less soluble and 
considerably less toxic Cr III form (20), these have also been used topically after skin exposure 
to Cr VI (53). Secondly to increase Cr elimination by maintaining urine output, by dialysis or 
by the addition of chelating agents (12,14,17,54,55). Thirdly using cytoprotective agents to 
limit cellular injury (48,56). A 10% solution of ascorbic acid, a reducing agent, was an effective 
antidote in rats (57), and a dose of 1 gm/24hrs was used as an oral adjunct to the successful 
therapy of a 2 year old child (20). There has been controversy in the medical literature over 
the effectiveness of dialysis in the removal of body Cr. Ellis et al. (17) reported Cr clearances 
varying between 3 to 23 ml/min during haemodialysis commenced three hours post ingestion, 
while Walpole et al.(20) reported minimal chromium elimination during peritoneal dialysis 
instituted 5 hours post ingestion. Kaufman et al.(14) performed peritoneal dialysis on day 3 
achieving an elimination of 22,4 mg of Cr in a 24 hour period, a plasma clearance of 2-3 
ml/min. Fristedt et al.(12) removed 24 mg of Cr by haemodialysis on day 7. Iserson et al. (18) 
used both early haemodialysis and charcoal haemoperfusion in an adolescent with very high 
blood Cr (58 mg/1) but found no significant removal of Cr Pederson and Morch (15) showed 
that 8 hours of haemodialysis with 2 dialysers in series accelerated the decline in serum Cr 
and concluded that dialysis was superior to the renal excretion of Cr. The effective removal 
of Cr by dialysis depends on the physicochemical state of the Cr containing ions and the 
degree of plasma protein, red cell and tissue binding. It has been shown that Cr VI readily 
enters the red cell (35), the hepatocyte (46) and the proximal renal tubular cells (41) where 
it is converted to the Cr III form which is not freely mobilised. Trivalent chromium in plasma 
is bound to transferrin and albumin with a biological half-life of 5-14 days which is not 
shortened by dialysis (32). Plasma water may contain colloidal or soluble complexes of Cr III 
(27). Colloidal Cr is rapidly taken up by the liver phagocytes (25). The soluble complexes 
formed with a variety of ligands, are readily excreted, and can cross dialysis membranes. 
Attention has only been paid to the quantitative excretion of Cr not to the form in which it 
is being excreted. The dog experiments of Collins et al. (33) suggested that all the excreted 
Cr was in the Cr III form and that the renal clearance of the blood dialysable Cr remained 
constant. None of the above clinical studies looked at dialysable Cr levels in the blood, but 
only at whole blood. In case 5 (Table VI) by separating the blood into red cells, plasma and 
plasma water, it has been shown that it is the plasma water Cr that is rapidly eliminated not 
the red cell or protein-bound Cr. This data is consistent with the animal experiments of 
Collins et al.(33) and can be put forward to explain the variable dialysis results noted above. 
The whole blood Cr level can not be expected to be a predictor of dialysability as its main 
components are red cell and protein bound Cr, both of which were shown in early Cr 51 
studies (31) to have prolonged biological half-lives unaffected by dialysis. Similarly serum Cr 
also may be largely composed of non-dialysable protein bound Cr. The interaction between 
tissue Cr and plasma water Cr is complex and may be affected by the presence of chelating 
agents (16,17), including citrate and acetate in dialysis fluids, tissue cell turnover and possibly 
iron status. If Cr VI cellular damage is the result of highly reactive intermediates such as Cr 
N and Cr V (46,47,48), then the elution of Cr III from cells would not be expected to affect 
the pathological processes of Cr VI toxicity. Early institution of dialysis is associated with an 
increased Cr clearance, but there is no evidence to suggest this is in the Cr VI form, more 
likely it is in the Cr III form. Dialysis performed at a later stage as in our cases, is supportive 
rather than therapeutic. The role of chelating agents also remains controversial. Dimercaprol 
(B.AL.) has been used clinically (12,17,20), however Ellis et al.(17) failed to show any benefit 
in animal studies. Poly-aminocarboxylic acid derivatives have been shown to be effective 
chelators in animals (54). An interesting development that requires clinical confirmation is 
the observation that N. acetylcysteine a free radical scavenger with chelating properties 
reduces dichromate induced renal injury in rats (57). Vitamin E an antioxidant (48) and 
thyroxine (56) have been shown to protect against Cr VI toxicity in animal models but this 
has not been confirmed clinically. 
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SUMMARY. 
Seven cases of acute dichromate poisoning following use of toxic purgatives are 
presented together with four post mortem forensic analyses. Toxicology screening revealed 
these four previously unexplained deaths to be the result of Cr VI poisoning. Thus a 
significant mortality and morbidity from Cr VI has been demonstrated. Although chronic 
industrial exposure to Cr VI is well recognised, only sporadic reports of acute toxicity have 
appeared in the medical literature. The cases reported in this thesis demonstrate that the 
incorporation of Cr VI into "traditional remedies" and the widespread use of these remedies 
poses a public health risk to the black population of South Africa. Attempts to contact the 
purveyors of these purgatives directly, were unsuccessful. At present there is no restriction 
on the distribution of dichromates, but as a result of these studies, the authorities have been 
approached with a request to have dichromates registered as toxic substances and distributed 
with appropriate health safety warnings. 
A review of the pathogenesis of Cr VI toxicity is presented, and is correlated with the 
chemistry of Cr. A hypothesis is proposed that the variability in clinical presentation is due 
in part, to the differing activity of intracellular reduction enzymes in organs. 
The role of dialysis in Cr elimination from the body is discussed, together with the 
controversy in the medical literature. Dialysis data is presented which suggests that it is only 
the plasma water Cr which is significantly dialysable, and that the dialysable content of blood 
is not directly related to either serum or whole blood Cr concentration. 
Because of the variable presentation of Cr VI poisoning and the denial of use of 
traditional medicines by some patients, a high index of suspicion for Cr VI toxicity should be 
maintained especially in cases of unexplained acute renal failure and even unexplained death. 
This thesis incorporates material which has been submitted for publication. 
"Acute dichrornate poisoning after use of traditional purgatives". South African Medical 
Journal, Jun 1990;77(12):640-642. 
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